SCHEMBL6988178

SCHEMBL6988178

Cc1ccc(C(=O)NC(Nc2c(Nc3cccnc3)c(=O)c2=O)C(C)(C)C)cc1

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 5/20 0.52
ABCC9 O60706 5/20 0.52
KCNJ11 Q14654 5/20 0.52
ABCC8 Q09428 4/20 0.52
KCNJ8 Q15842 4/20 0.52
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPC1 O15118 4/20 0.45
RAB9A P51151 4/20 0.45
MAPKAPK2 P49137 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6989283 0.92 ABCC9 (0.51) NAMPTABCC9KCNJ11ABCC8KCNJ8
SCHEMBL7555212 0.92 ABCC9 (0.51) NAMPTABCC9KCNJ11ABCC8KCNJ8
SCHEMBL6981921 0.91 ABCC9 (0.64) NAMPTABCC9KCNJ11ABCC8KCNJ8
SCHEMBL6991578 0.91 ABCC9 (0.51) NAMPTABCC9KCNJ11ABCC8KCNJ8
SCHEMBL6983541 0.90 MAPKAPK2 (0.52) ABCC9KCNJ11ABCC8KCNJ8MEN1
SCHEMBL6984352 0.89 ABCC9 (0.47) NAMPTABCC9KCNJ11ABCC8KCNJ8
SCHEMBL6982343 0.89 CYP1A2 (0.56) ABCC9KCNJ11ABCC8KCNJ8MEN1
SCHEMBL6990454 0.86 ABCC9 (0.52) ABCC9KCNJ11ABCC8KCNJ8MEN1
SCHEMBL6987810 0.86 ABCC9 (0.47) ABCC9KCNJ11ABCC8KCNJ8MEN1
SCHEMBL6985809 0.85 ALDH1A1 (0.47) ABCC9KCNJ11ABCC8KCNJ8MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1358160-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2003-11-05 EP claimed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US claimed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US claimed
US-20020147230-A1 Aminal Diones as potassium channel openers ABBOTT LABORATORIES 2002-10-10 US claimed
WO-2002062761-A1 AMINAL DIONES AS POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2002-08-15 WO claimed
US-6495576-B2 N-(1-((3,4-DIOXO-2-(3-PYRIDINYLAMINO)-1-CYCLOBUTEN-1-YL)AMINO) -2,2-DIMETHYLPROPYL)-4-METHYLBENZAMIDE FOR EXAMPLE; TREATING BLADDER OVERACTIVITY, BENIGN PROSTATIC HYPERPLASIA, PREMATURE LABOR, AND SEXUAL DISORDERS ABBOTT LABORATORIES 2002-12-17 US disclosed
US-20020165264-A1 Aminal diones as potassium channel openers ABBOTT LABORATORIES 2002-11-07 US disclosed
US-20020147230-A1 Aminal Diones as potassium channel openers ABBOTT LABORATORIES 2002-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147230-A1 Aminal Diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 NAMPT 1144/4885ABCC9 1043/4885KCNJ11 2/4885
US-20020165264-A1 Aminal diones as potassium channel openers KCNJ2, KCNJ11, KCNH1 NAMPT 1144/4885ABCC9 1043/4885KCNJ11 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.